AXLRx Book a callCommission

Small–Mid · Company profile

KalVista

Commission a KalVista report

By therapy area

Therapy area All areas Rare Disease

AXLRx reports featuring KalVista

CI · Rare Disease · CI Team · Launch Lead · Market Access US Hereditary Angioedema Competitive Intelligence The prophylaxis class is fracturing along route: oral berotralstat and the first oral on-demand agent against a still-injectable antibody field. US · In-Market · Read report → DL · Rare Disease · CI Team · Launch Lead US Hereditary Angioedema Disease Landscape HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape. US · In-Market · Read report → P&HTA · Rare Disease · Market Access · Medical Affairs US Hereditary Angioedema Payer & HTA Specialty-tier prior authorization, prophylaxis above $300K/patient/yr, ICER 2018/2021 value-based benchmarks and no-concurrent-acute-agent rules. US · In-Market · Read report →